Skip to main content

Table 4 Evolution in overall cognitive outcomes, executive function and attention according to combined plasma MCP-1 and Aβ42/40 status

From: Plasma MCP-1 and changes on cognitive function in community-dwelling older adults

Period

Aβ42/40−a/MCP1−b

n = 195

Aβ42/40−/MCP1+

n = 85

Aβ42/40+ /MCP1−

n = 97

Aβ42/40+ /MCP1+

n = 52

Between-group difference (95% CI)c

Between-group difference (95% CI)c

Between-group difference (95% CI)c

Between-group difference (95% CI)c

Cognitive Composite Scored,n= 383

 12 months

−0.09 (−0.12, −0.05)

−0.08 (−0.18, −0.03)

−0.24 (−0.39, −0.10)***

−0.23 (−0.42, −0.04)**

 24 months

−0.06 (−0.10, −0.03)

−0.08 (−0.19, 0.03)

−0.43 (−0.58, −0.27)***

−0.28 (−0.48, −0.07)**

 36 months

−0.16 (−0.20, −0.12)

−0.28 (−0.24, −0.00)

−0.39 (−0.56, −0.21)***

−0.23 (−0.44, −0.01)*

 48 months

−0.19 (−0.24, −0.15)

−0.13 (−0.26, −0.004)

−0.40 (−0.59, −0.21)***

−0.41 (−0.65, −0.17)***

MMSE,n= 383

 12 months

−0.12 (−0.26, 0.01)

−0.09 (−0.38, 0.21)

−0.45 (−0.87, −0.04)*

−0.50 (−1.03, 0.02)

 24 months

−0.06 (−0.20, 0.08)

−0.21 (−0.52, 0.10)

−0.99 (−1.43, −0.55)***

−0.36 (−0.91, 0.20)

 36 months

−0.28 (−0.43, −0.13)

0.01 (−0.33, 0.36)

−0.60 (−1.11, −0.08)*

−0.28 (−0.90, 0.35)

 48 months

−0.21 (−0.37,−0.05)

−0.13 (−0.49, 0.23)

−0.69 (−1.23, −0.15)*

−0.66 (−1.35, 0.02)

CDR sum of boxes,n= 383

 12 months

0.14 (0.08, 0.20)

0.11 (−0.002, 0.22)

0.08 (−0.08, 0.24)

0.24 (0.04, 0.44)*

 24 months

0.13 (0.06, 0.20)

0.17 (0.03, 0.31)

0.13 (−0.07, 0.34)

0.34 (0.08, 0.59)*

 36 months

0.23 (0.15, 0.31)

0.12 (−0.06, 0.30)

0.22 (−0.05, 0.48)

0.31 (−0.01, 0.64)

 48 months

0.33 (0.23, 0.43)

0.15 (−0.07, 0.36)

0.37 (0.06, 0.68)*

0.54 (0.15, 0.93)*

Executive function composite scoree,n= 376

 12 months

−0.02 (−0.05, 0.02)

−0.05 (−0.17, 0.06)

−0.32 (−0.49, −0.15)***

−0.13 (−0.35, 0.08)

 24 months

−0.04 (−0.08, −0.004)

−0.07 (−0.17, 0.06)

−0.34 (−0.52, −0.17)***

−0.20 (−0.43, 0.02)

 36 months

−0.10 (−0.14, −0.05)

−0.08 (−0.21, 0.06)

−0.39 (−0.58, −0.19)***

−0.24 (−0.48, 0.01)

 48 months

−0.12 (−0.17, −0.07)

−0.10 (−0.24, 0.05)

−0.41 (−0.62, −0.20)***

−0.21 (−0.48, 0.06)

Attention scoref,n= 383

 12 months

−0.03 (−0.05, 0.00)

0.00 (−0.09, 0.09)

−0.11 (−0.24, 0.02)

−0.13 (−0.29, 0.03)

 24 months

−0.03 (−0.06, −0.01)

−0.01 (−0.11, 0.08)

−0.17 (−0.30, −0.03)

−0.21 (−0.38, −0.04)*

 36 months

−0.10 (−0.13, −0.07)

−0.04 (−0.14, 0.06)

−0.12 (−0.27, 0.02)

−0.23 (−0.41, −0.05)*

 48 months

−0.13 (−0.17, −0.10)

−0.04 (−0.14, 0.07)

−0.19 (−0.34, −0.04)*

−0.29 (−0.48, −0.09)**

  1. *p value < 0.05; ** p value < 0.001; ***p value < 0.001: significant differences in the evolution of the outcomes (Aβ42/40−/MCP1− as reference group)
  2. #p value < 0.05; ##p value < 0.001; ###p value < 0.001: significant difference in the evolution of the outcomes between Aβ42/40+ /MCP1− and Aβ42/40+/MCP1+ groups
  3. Models were adjusted by sex, age, BMI, MAPT group, CDR status at baseline, GDS score, and ApoE ε4 genotype
  4. Abbreviations: Aβ42/40 β-amyloid 42aa isoform/β-amyloid 40aa isoform ratio, MCP-1 Monocyte Chemoattractant Protein-1, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating
  5. aAbnormal Aβ42/40 defined as values ≥ 107 pg/mL
  6. bAbnormal MCP-1 defined as values in the 4th quartile (> 251 pg/mL)
  7. cNegative values indicate worsening performance along follow-up, except for CDR sum of boxes (for which it is given by positive values)
  8. dBased on the z-score of 4 cognitive tests (free and total recall of the Free and Cued Selective Reminding test; 10 MMSE orientation items; Digit Symbol Substitution Test, and Category Naming Test)
  9. eBased on the z-score of 3 executive function tests (Controlled Oral Word Association Test, the Category Naming Test and the Trail Making Test-Part B)
  10. fBased on the z-score of 2 attention tests (Digit Symbol Test and the Trail Making Test-Part A)
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193